A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT)
The main aim of the study is to check if treatment with maribavir can protect Japanese people
against Cytomegalovirus (CMV) infection, and to check side effect from the study treatment
and how much maribavir participants can take without getting side effects from it.
Japanese recipients of a hematopoietic stem cell transplant (HSCT) or solid organ transplant
(SOT) will take Maribavir tablets two times a day for 8 weeks in this study.
During the study, participants will visit their study clinic 18 times as a maximum.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.